Abbott and Dexcom Navigate Evolving Coverage Rules for Diabetes Technology Ahead of Medicare Changes
Medical technology leaders Abbott Laboratories and Dexcom are responding differently to market conditions and pricing pressures as the healthcare industry prepares for a planned expansion of Medicare coverage for continuous glucose monitoring devices.
Market Dynamics Ahead of Coverage Expansion
Abbott reported facing pricing pressures and slower growth metrics as it anticipates the upcoming policy changes regarding Type 2 diabetes management tools. Continuous glucose monitoring systems have become a standard of care for many individuals managing diabetes, allowing patients to track glucose levels in real time without frequent finger-prick blood tests.
Varying Business Impacts Across Manufacturers
While Abbott noted challenges related to pricing and growth rates leading up to the anticipated Medicare policy shift, competitor Dexcom stated that it did not encounter the same slowdown during the comparable period. Both companies continue to monitor regulatory developments closely as public and private payers adapt their reimbursement frameworks to accommodate broader populations of patients with Type 2 diabetes.
Key Considerations for Patients and Providers
- Medicare coverage expansions aim to improve device accessibility for individuals with Type 2 diabetes.
- Manufacturers report varying financial and market impacts as reimbursement policies evolve.
- Continuous glucose monitoring technology remains a focal point in modern chronic disease management strategies.
